Alkermes to Present New Data on Psychiatry and Orexin Portfolios at ASCP Meeting
Event summary
- Alkermes will present new clinical and real-world data on its psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting from May 26-29, 2026.
- Poster presentations include data on LYBALVI, ARISTADA, and investigational orexin 2 receptor agonists like alixorexton, ALKS 4510, and ALKS 7290.
- Key topics include the impact of cognitive impairment and fatigue on work productivity in narcolepsy and idiopathic hypersomnia, and real-world adherence to LYBALVI compared to other antipsychotics.
- Phase 2 data on alixorexton for narcolepsy type 1 will be presented, including patient-reported disease severity and cognitive functioning.
- The event highlights Alkermes' focus on advancing treatments for complex psychiatric and neurological conditions.
The big picture
Alkermes is positioning itself as a leader in neuroscience and psychiatry by showcasing its deep scientific expertise and innovative pipeline. The focus on orexin biology reflects a strategic shift towards addressing complex neuropsychiatric conditions, which could open new market opportunities. The company's ability to translate clinical and real-world data into commercial success will be a key factor in its long-term growth.
What we're watching
- Pipeline Progress
- The pace at which Alkermes advances its orexin 2 receptor agonist pipeline, particularly alixorexton, will be critical for expanding its neuroscience portfolio.
- Market Differentiation
- Whether Alkermes can differentiate LYBALVI and ARISTADA in the competitive antipsychotic market through real-world evidence and clinical data.
- Regulatory Pathways
- The potential for Breakthrough Therapy designation to accelerate the development and approval of alixorexton for narcolepsy type 1.
Related topics